Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B5
Source: 0001628280-25-017695
Chunk: 17

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B5
Chunk 17
---
 we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

The above table and discussion of shares of our common stock that will be outstanding after this offering is based on 27,531,490 shares of our common stock outstanding as of December 31, 2024, and excludes, in each case as of December 31, 2024:

• 164,676 shares of our common stock issuable upon the exercise of warrants to purchase shares of our common stock outstanding as of December 31, 2024, with an exercise price of $10.64 per share;

• 1,458,939 shares of our common stock issuable upon the exercise of outstanding options under 2020 Plan, which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $4.28 per share;

<div align='center'>S-13</div>

• 8,438 shares of our common stock issuable upon the exercise of outstanding options under the 2021 Plan, with a weighted average exercise price of $11.94 per share;

• 1,522,550 shares of our common stock issuable upon the exercise of outstanding options under the 2024 Plan, with an exercise price of $16.45 per share;

• 790,139 shares of common stock issuable upon the exercise of stock options granted pursuant to the 2024 Plan subsequent to December 31, 2024, with a weighted average exercise price of $26.00 per share;

• 30,500 shares of common stock issuable upon the vesting of restricted stock units granted pursuant to the 2024 Plan subsequent to December 31, 2024;

• 1,544,122 shares of our common stock reserved for future issuance under our 2024 Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and

• 250,995 shares of our common stock reserved for future issuance under our 2024 ESPP, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan.

Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options after December 31, 2024.

The share numbers set forth above also exclude the automatic increases in the shares reserved under the 2024 Plan and the 2024 ESPP that were effective